Core Viewpoint - Deqi Pharmaceutical-B (06996) reported a decrease in revenue for the six months ending June 30, 2025, with a total income of RMB 53.182 million, reflecting a year-on-year decline of 12.5% [1] Financial Performance - Revenue for the six months ending June 30, 2025, was RMB 53.182 million, down from RMB 60.80 million for the same period in 2024, a decrease of RMB 7.60 million [1] - Research and development costs amounted to RMB 79.935 million, a significant reduction of 38.91% year-on-year [1] - Adjusted loss for the period was RMB 72.858 million, which is a decrease of 52.25% compared to the previous year [1] - Earnings per share showed a loss of RMB 0.12 [1] Market Dynamics - The inclusion of the drug Cevinostat (希维奥) in the 2023 National Medical Insurance Directory in December 2023 initially drove strong market growth expectations for the six months ending June 30, 2024 [1] - Following the initial surge, market demand has gradually returned to a more rational state [1] - Revenue for the six months ending June 30, 2025, increased by RMB 22 million compared to the second half of 2024, indicating steady growth and stability in revenue [1]

Core Insights - The latest data from the Hong Kong Stock Exchange indicates that on August 18, shareholders of Deking Pharmaceutical-B (06996) deposited shares worth HKD 416 million into Standard Chartered Bank (Hong Kong), representing 9.23% of the total shareholding [1] - On July 28, Deking Pharmaceutical announced that the National Medical Products Administration (NMPA) of China has approved the use of Xivio (Selinexor) in combination with Bortezomib and Dexamethasone (XVd) for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received at least one prior therapy, marking a new indication for Xivio [1]